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A combined vaccine against Peste des Petits Ruminants (PPR) and Sheep/Goat Pox (SGP) was developed
and applied in the ﬁeld, using a new association of vaccine strains: PPR Nigeria 75 strain with a titre of
104.1 TCID50 and Sheep Pox Romania strain with a titre of 104.0 TCID50. Safety and efﬁcacy were evalu-
ated on goats and sheep in comparison with monovalent PPR and SGP vaccines. Goats were challenged by
PPR virulent strain and sheep by SP virulent strain. The result shows that the combined PPR/SGP vaccine
confers a good protection against both PPR and SGP infection with no signiﬁcant difference with mono-
valent vaccines. The combined vaccine was used in the ﬁeld on sheep ﬂocks and good sero-conversion
was detected for both diseases as soon as 14 days post vaccination.
 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The production of small ruminants is threatened by economi-
cally important contagious diseases: the Peste des Petits
Ruminants (PPR) and Sheep/Goat Pox (SGP). Both PPR and SGP
are transboundary animal diseases listed by the World
Organization of Animal Health (OIE).
The control of PPR and SGP is a major goal for a program aimed
to poverty alleviation because of the high importance of sheep and
goats in endemic regions. The available monovalent vaccines for
the control of both PPR and SGP protect after a single injection
and the induced immunity covers at least the economic life of
the animals, around three 3 years [1–3]. However, the low vaccina-
tion coverage due to large space distribution of the animal pop-
ulation and poor infrastructure with difﬁcult access contribute to
spread or maintain the infection.
It could be interesting to use an associated bivalent vaccine that
protects against the two infections in one shot and this may pro-
mote a wider use of vaccination since both diseases are found inthe same region. Similar associated vaccines against PPR and SGP
infections has been developed in the past and used experimentally
with satisfactory results in India [4,5] and in Cameroon [6].
However, no mass vaccination has been conducted with the asso-
ciated vaccine so far.
The objective of this study was to develop and apply for mass
vaccination a combined vaccine that could be used to protect in
one-shot small ruminants against both PPR and SGP. The beneﬁts
of opting for a single vaccination covering both diseases (PPR and
SGP) are numerous: to provide comfort to farmers, reduce stress
in animals, especially minimizing vaccination costs for professional
farming sector. The combined vaccine was based on highly
immunogenic worldwide used strains of PPR (Nigeria 75) and SP
(Romania). This strain association was tested for the ﬁrst time.
2. Material and methods
2.1. Viral strains
The live PPR vaccine strain was Nigeria 75 developed by Diallo
et al. [7], for SGP was the Sheep Pox Romania strain [8]. Both
strains grown on Monkey African Green kidney (VERO) cells are
commonly used for the protection of SGP and PPR.
Local isolated virulent strains: PPR MOR 2008 and SP MOR 1998
were selected for the challenge. Those strains are routinely used in
our laboratory for potency testing of monovalent vaccines and
characteristic symptoms are observed after experimental infection.
Fig. 1. Neutralizing PPR antibody response and PPR ELISA antibody response after
vaccination of goats by combined and monovalent vaccines (group average).
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Vaccine strains were grown separately on roller bottles with
conﬂuent cells, the inoculation was done using the same multiplic-
ity of infection (M.O.I.) of 0.01. Viral suspensions were harvested
when 80% of CPE was observed which happened 3–4 days for
PPRV and 4–6 days for SGPV. The viral suspension was then stored
at 80 C before use.
From those two antigens, a monovalent PPR vaccine, a monova-
lent SGP vaccine and a combined PPR/SGP vaccine, all on lyophi-
lized forms were prepared for this study. Vaccines were
formulated in appropriate concentration of PPR and/or SGP for
the recommended titre, mixed V/V with a stabilizer of lyophilisa-
tion (4% peptone, 8% sucrose and 2% glutamate).
For vaccination, the freeze-dried vaccine vial of 100 doses was
reconstituted in 50 ml of the diluent (saline solution) for a vaccine
dose of 0.5 ml.
2.3. Vaccination of sheep and goats
Animal experiment was carried out in accordance with guide-
lines for care and handling of experimental animals, as per the lab-
oratory committee for purpose of control and supervision of
experiments on animals. The experiment was conducted on four
groups of animals housed in the animal unit of MCI Santé
Animale, Mohammedia, Morocco: Group 1 composed by 6 sheep
and 6 goats vaccinated with the combined SGP/PPR, Group 2 com-
posed by 4 sheep vaccinated with the monovalent SP, Group 3
composed by 4 goats vaccinated with the monovalent PPR and
Group 4 composed by unvaccinated animals (2 goats and 2 sheep).
Common local breed sheep and Alpine goats were used in this
experiment. All animals were aged 6–8 months, and tested sero-
negative for PPR and SGP.
Vaccination of each group was conducted by subcutaneous
route and the monitoring consisted on a clinical observation, tem-
perature, injection site inﬂammation and serological response.
2.4. Determination of vaccine potency
Determination of the vaccine potency was carried out by chal-
lenge on BSL3 containment laboratory.
Goats were challenged at day (D) 28 post vaccination by intra-
venous (IV) injection and intra-nasal (IN) spray of PPRV virulent
strain according to the protocol of Elharrak et al. [9]. The titre of
the virulent strains was 105.4 ID50/ml and the dose was 1 ml IN
and 1 ml IV. Sheep were challenged at D28 by the SP virulent strain
with a titre of 105.5 ID50/ml, using the protection index protocol
that consisted on a virus titration by intra-dermal injection of
serial dilutions on the ﬂank of each animal. The obtained titre for
each group was compared with the titre of the unvaccinated con-
trol animals and the difference between the two titres expressed
in log represent the protection index [10].
The monitoring consisted on daily observations of speciﬁc
symptoms, temperature and local inﬂammation on the site of
injection. Clinical scoring and protection index, for each animal
and the average for the group was calculated. All surviving animals
were euthanized at D14 post infection, autopsied and sampled for
further investigations.
2.5. Field trial of combined PPR/SPG vaccine
The combined vaccine was tested in the normal conditions of
the ﬁeld in three farms located in regions nearby Rabat. Three
ﬂocks of a minimum of 200 heads of local sheep, between
6 months and 5 years of age, have been used in the trial, observed
3 weeks for the vaccine safety and monitored weekly forserological response. Analyses were carried out on 10% of the vac-
cinated population.
To monitor vaccination response for both PPR and SGP, serologi-
cal testing has been done using virus neutralization test as
described in the OIE Terrestrial Manual (Chapters 2.7.11 and
2.7.14). ELISA test was also used to detect PPR kinetic of antibodies
following vaccination. The kit ‘ID Screen PPR Competition’ refer-
ence (PPRC-4P ID-VET) was used for that purpose [11].
For the antigen detection on challenged animals, we used real
time qPCR as described by Batten et al. [12] for PPR and by
Bowden et al. [13] for SGP. DNA extraction was performed using
isolate genomic DNA/RNA Mini kit (Bioline BIO-52066 & BIO-
52075) and ampliﬁcation done with the Kkit superscript Tm III
Platinum R one step qRt-PCR system (Cat. No. 11745-100).
2.6. Statistical analysis
To compare serological responses to monovalent and combined
vaccines, data were entered into a database using SPSS 20.0 for
Windows (SPSS Inc., Chicago, USA). The independent samples t test
was used for continuous variables. The difference was considered
signiﬁcant if p-value was <0.05.3. Results and discussion
The PPRV growth with characteristic cytopathogenic effect
(CPE) on VERO cells, speciﬁc syncytia leading to necrosis was
observed after 4–5 days of incubation. The obtained infectious titre
was 6.1 ± 0.2 TCID50/ml of the harvested suspension. SPV induced
a CPE after 4–5 days of incubation and the titre of the harvested
suspension is 5.5 ± 0.2 TCID50/ml.
In this experiment, a monovalent PPR vaccine, a monovalent
SGP vaccine and a combined PPR/SGP vaccine, on lyophilized forms
were produced. The three vaccines were tested for sterility, purity
and identity according international standards. The infectious titre
per dose for these vaccines were 104.1 TCID50 for PPR, and 104.0
TCID50 for SGP.
Safety and efﬁcacy of the vaccination was evaluated on animals
comparatively between combined and monovalent vaccines.
During the three 3 weeks following vaccination, all vaccinated ani-
mals remained healthy, without any effect on their appetite and
Fig. 2. Neutralizing PPR antibody response and PPR ELISA antibody response after
vaccination of sheep by combined and monovalent vaccines (group average).
Fig. 3. Neutralising SPV antibody response after vaccination of sheep by combined
and monovalent vaccines (group average).
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of a small transitory nodules and a short increase of the tempera-
ture not exceeding 1 C during 2 days in sheep of Group 1 and
Group 2. This reaction is routinely observed with Sheep Pox live
attenuated vaccine based on Romania strain [8].Table 1
Results of vaccinated and unvaccinated goats challenged by PPR virulent strain.
Animal Clinical
scoring
Mortality Maximum viral charge in ocu
swab (Ct value)
Combined SPV-PPR 134 0 – 37.1
146 0 – >34.6
172 0 – 34
182 0 – >30.1
Monovalent 132 0 – >34.2
166 2 – 37.1
Unvaccinated 164 19 D8 23.9
150 17 D10 19.6Serological response after vaccination is reported in Figs. 1–3.
Good SGP antibody response obtained as soon as 7 days post
vaccination. The neutralisation titre seems to stabilize between
1.8 and 2 log (Fig. 3).
Regarding PPR, the antibody titre increased progressively in
goats until D28 with no signiﬁcative difference (p > 0.05) between
combined or monovalent vaccine as tested by SN and conﬁrmed by
ELISA (Fig. 1). For sheep a similar response was obtained with PPR
antibodies after vaccination (Fig. 2). No signiﬁcant difference in
serological response between monovalent and combined vaccine
or between sheep and goats regarding PPR valence. A similar
observation was reported by Ayalet et al. [14] and by Chaudhary
et al. [4].
Regarding SGP, serological response tested in sheep after
vaccination show no signiﬁcant difference between monovalent
and combined vaccine. This valence has not been tested on goats
because it has been demonstrated previously that Romania strain
provides good protection against Goat Pox infection: vaccinated
goats challenged with a virulent strain of Goat Pox virus appears
to be fully protected (unpublished data). This cross protection
between genus of Capripoxviruses have been reported by several
authors [15,16].
Both vaccinated and unvaccinated control animals were chal-
lenged 28 days after vaccination by the corresponding virulent
strain.
PPR challenge was conducted on goats and the obtained results
are described in Table 1. Unvaccinated animals showed speciﬁc
clinical signs of PPR infection: dyspnoea, nasal and ocular dis-
charge followed by a respiratory syndrome with painful polypnea
and profuse diarrhea in the terminal stage. The body temperature
exceeded 40.8 C. The two unvaccinated control goats died at D8
and D10 post infection with a clinical scoring of 19 and 17 respec-
tively. Analysis by qPCR showed a high level of viral multiplication
with excretion detected in ocular and rectal swabs (Ct 14.7). At
post mortem examination, speciﬁc lesions of pneumonia and
inﬂammatory nodules were observed in lung and digestive tractus
with high viral concentration as detected by qPCR (Ct 17.9 in
mesenteric nodes and 19.4 in lungs).
The obtained results complain with other studies on Alpine
goats reported by Hammouchi et al. [17] and Elharrak et al. [9]
whose deﬁned a challenge model for PPR. However other experi-
mental infection carried by several authors shows irregular or
non-conclusive results depending on the animal species and
breeds, the challenge strain and inoculated doses [18]. For vacci-
nated animals with monovalent PPR or combined vaccine, no clini-
cal symptom was reported during the 14 days of observation
period, the body temperature remained normal and the clinical
scoring estimated between 0 and 2. PCR testing of ocular and rectal
swabs of vaccinated and challenged animals conﬁrmed the absence
of virus excretion. These give evidence that combined and mono-
valent vaccines provide complete protection against the disease
and the infection with PPRV.lar Maximum viral charge in rectal
swab (Ct value)











Results of vaccinated and unvaccinated sheep challenged by SP virulent strain.
Identiﬁcation Serology (log neutralisation doses 50%) Infectious titre (ID50/0.2 ml) Protection value
Unvaccinated sheep 958 0 5.5 0.4
957 0 5.9 0
Sheep vaccinated by combined vaccine 951 1.98 0 5.7
952 1.26 0 5.7
953 1.26 0 5.7
954 1.74 0 5.7
Sheep vaccinated by SPV Ro monovalent vaccine 955 2.46 0 5.7
956 1.98 0 5.7
Maximum viral charge (Ct value) for unvaccinated sheep
Primary lesions Secondary lesions Nodes Organs
Inoculation site Skin papules Mesenteric Pulmonary Lung Spleen
11.3 12.9 9.72 17.2 27.2 Undetermined
10 -1      10 -2     10 -3 10 -4 10 -5       10 -6
Fig. 4. Figure of a challenged control sheep showing local inﬂammation on site of
inoculation (ﬂank) with 10–1 to 10–6 dilutions (left to right) of virulent SGPV in ﬁve
replica.
36 F. Fakri et al. / Trials in Vaccinology 4 (2015) 33–37SGP challenge was conducted on sheep and the obtained results
are described in Table 2. The used challenge model allows quan-
tiﬁcation of the conferred immunity and then comparison between
different vaccines.Fig. 5. Percentage of seroconversion for PPR and SPV of vaccinatAfter challenge, unvaccinated sheep showed local inﬂammation
in the site of injection (Fig. 4) starting at D3 pi at the lowest dilu-
tion with the maximum reaction observed between D7 and D9. The
two control animals presented hyperthermia with a peak value up
to 41.4 C at D7 pi, and secondary lesions from D8. The obtained
titre was 5.5 and 5.9 ID50/0.2 ml in the two controls respectively.
After euthanasia at D14 pi, qPCR analysis showed a maximum viral
charge with a Ct 11.3 in primary lesions (inoculation site), Ct 12.9
in secondary lesions (skin papules); an important viral charge was
also observed in some nodes (Ct 9.72 in mesenteric nodes, to 17.2
in pulmonary node) and a low charge in lung (Ct 27.2) and negative
in spleen.
Regarding vaccinated sheep, no clinical sign of the disease was
observed and no secondary lesion reported for both monovalent
and combined vaccine. After the challenge virus injection in the
animal ﬂank, a hypersensibility reaction was observed after the
ﬁrst and the second day pi which disappear completely the follow-
ing days. No inﬂammatory reaction reported in the injection sites
even in the lowest dilution giving evidence of the complete neu-
tralisation of the virulent virus by the conferred immunity.
Similar results have been also reported by Precausta et al. [8],
whose authors demonstrated that Romania strain is very effective
for protection against Sheep Pox infection. The protection index
was evaluated to 5.7 ID50/0.2 ml in vaccinated sheep which mean
a solid and durable immunity. In support of the presented sheep by the combined PPR/SGP vaccine in three farms.
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by Chaudhary et al. [4] showed that all the immunized animals
resisted challenge with virulent SPV or PPRV, while control animals
developed characteristic signs of disease.
Consequently, the combined vaccine was tested at large scale
under normal ﬁeld conditions on three ﬂocks of sheep in the cen-
tral region of Morocco as described in material and methods.
Results were expressed by percentage of seropositive animals as
tested by SN for PPR and SGP (Fig. 5).
In two farms, few animals were found positive for PPR due to a
previous vaccination. The global serological response obtained by
ELISA reaches almost 100% at D14 after vaccination with some dif-
ferences between farms. When tested by SN, 75% of the animals
were protected at D14 and 100% at D21 against PPR (Fig. 5). This
difference between the two technics could be explained by high
sensitivity of ELISA compared to SN. For SGP 65% of animals were
protected at D14 to around 90% at D21 (Fig. 5). Consistent results
were published by Hosamani et al. [5] using combined PPR and
Goat Pox vaccine and by Sreenivasa et al. [2] using PPR vaccine
only.
4. Conclusion
In conclusion the combined PPR/SGP vaccine confers a good
protection against both PPR and Sheep Pox infections and diseases.
At laboratory level solid protection was obtained with no viral
multiplication in vaccinated and sssschallenged animals, results
conﬁrmed by serology monitoring after large scale vaccination
under normal ﬁeld conditions. The combined vaccine could be used
for vaccination campaigns to protect small ruminants in one shot
against two economically and medically important diseases. The
combined vaccine could be an efﬁcient tool in endemic countries
with low infrastructure and extensive breeding management of
small ruminant population. In addition, it could be interesting to
use this combined vaccine to reduce vaccination costs which might
be highly attractive for farmers in these countries.
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